Cancer survivorship is a concept that has fundamentally reshaped how oncologists, patients, and health systems think about cancer care. For most of the twentieth century, the goals of cancer treatment were straightforward: eliminate the cancer or control its growth. The question of what happened to people after treatment — how they lived, what physical and psychological burdens they carried for years or decades, and what healthcare they needed long after the oncologist’s work was ostensibly done — received little systematic attention.
That changed. Today, there are 18.1 million cancer survivors living in the United States alone, a number the American Cancer Society projects will grow to 26.1 million by 2040. Cancer survivorship is now understood as a distinct phase of the cancer experience, one with specific medical, psychological, social, and behavioral needs that differ meaningfully from the acute treatment phase and that require dedicated clinical attention.
What Is Cancer Survivorship?
The modern definition of cancer survivorship comes from the National Cancer Institute: survivorship encompasses the period “from the time of diagnosis through the balance of life.” Under this definition, cancer survivorship is not something that begins when treatment ends — it begins at diagnosis and never technically ends.
This definition owes a great deal to physician Fitzhugh Mullan, who published a personal and conceptual essay in the New England Journal of Medicine in 1985 titled “Seasons of Survival: Reflections of a Physician with Cancer.” Mullan articulated three “seasons” that characterize the cancer survivorship experience:
From diagnosis through initial treatment — dominated by medical decisions, physical side effects, and the shock of the diagnosis. The focus is on surviving treatment and responding to the cancer.
Post-treatment watchful waiting — characterized by surveillance, the emergence of late effects, fear of recurrence, and the psychological challenge of living with ongoing uncertainty. May last years.
Cancer appears controlled long-term. For some cancers, functionally equivalent to cure. For others, living with chronic cancer or lifelong elevated risk remains the defining reality.
The 18.1 million Americans counted as cancer survivors span all three seasons: people currently in active treatment, people in remission undergoing surveillance, and people who completed treatment many years ago. The “5-year survival” milestone is clinically meaningful for many cancer types but does not mark the end of cancer survivorship — for hormone receptor-positive breast cancer, recurrence risk continues for 20 years; for prostate cancer, late recurrences at 10–15 years are documented; for childhood cancer survivors, elevated health risks from treatment persist for life. Cancer survivorship is a lifelong experience, and the 5-year mark is a clinical benchmark rather than a finish line.
Survivorship Care Plans — What They Are and Why You Need One
In 2005, the Institute of Medicine published a landmark report titled “From Cancer Patient to Cancer Survivor: Lost in Transition.” The report identified a profound gap: the millions of Americans who completed cancer treatment were being discharged from active oncology care without adequate preparation for the years ahead. Most received no summary of their treatment, no guidance on what late effects to watch for, no surveillance schedule specific to their treatment exposure, and no roadmap for transitioning back to primary care.
The report’s central recommendation was the survivorship care plan (SCP): a written document provided at the completion of primary treatment summarizing the cancer diagnosis, treatments received (specific agents and doses), a surveillance schedule, late effects to watch for specific to the treatments received, and health behavior and psychosocial support guidance. The ASCO survivorship care plan template is the most widely used structured SCP format in the United States and can be accessed through the ASCO cancer.net patient website.
Late Effects — The Long Shadow of Cancer Treatment
Late effects are medical complications of cancer treatment that emerge or become apparent months to years after treatment has been completed. They are distinct from acute side effects (which typically resolve) and from cancer recurrence. Late effects are treatment toxicities with long latency periods — the result of cellular and organ-level damage that may not manifest until long after treatment ends.
Anthracycline cardiomyopathy: may manifest 5–20 years post-treatment. Chest radiation: coronary artery disease; +7.4% per Gray of mean cardiac dose (Darby SC, NEJM 2013). Echocardiogram every 2–5 years for high-risk survivors.
Therapy-related AML from alkylating agents/etoposide: 1–2% at 10 years. Radiation-related solid tumors: risk peaks 10–20 years post-treatment. Childhood survivors: ~9% cumulative incidence at 30 years (Friedman DL, JCO 2010).
Bleomycin-related pulmonary fibrosis: dose-dependent; DLCO monitoring required in Hodgkin lymphoma survivors. Radiation pneumonitis → fibrosis from chest RT.
CIPN (persistent in 30–40%); cranial radiation → cognitive decline; IQ effects and attention deficits most severe in young children at time of radiation.
Premature menopause from alkylating agents; hypothyroidism after neck radiation or immunotherapy; hypogonadism in men after ADT or pelvic radiation; infertility from pelvic radiation.
Osteoporosis from AIs, ADT, and corticosteroids; avascular necrosis (hips, shoulders) from corticosteroids; lymphedema from lymph node surgery/radiation.
For childhood cancer survivors, the breadth and lifelong persistence of late effects warrants specialized follow-up through COG Long-Term Follow-Up Guidelines (survivorshipguidelines.org). The Childhood Cancer Survivor Study found that 40% of excess late mortality in childhood cancer survivors is from secondary malignancies, 26% from cardiac causes, and 11% from pulmonary causes (Armstrong GT et al., J Clin Oncol 2009) — confirming that the diseases that kill long-term cancer survivors are often consequences of the treatments that saved their lives.
Mental Health and Psychological Survivorship
The psychological dimensions of cancer survivorship are among the most prevalent, the most impactful on quality of life, and the least consistently addressed in clinical practice. Fear of cancer recurrence is the most commonly reported psychological concern: between 49% and 70% of survivors report clinically significant fear that their cancer will return — approximately 30% experience severe fear that substantially impairs daily life and functioning (Simard S et al., J Pain Symptom Manage 2013). Randomized controlled trials have demonstrated that structured psychological interventions — including the Conquer Fear program (Butow PN et al., J Clin Oncol 2017) — significantly reduce fear severity in cancer survivors. See the cancer remission article for a deeper discussion of fear of recurrence and scanxiety.
Cancer-related PTSD affects 4–22% of survivors. Major depression affects approximately 16.5% of patients in oncology settings (Mitchell AJ et al., Lancet Oncol 2011); clinically significant anxiety affects an additional 10–30%. Alongside distress, approximately half of cancer survivors report post-traumatic growth — positive psychological changes including heightened appreciation for life, more meaningful relationships, recognition of personal strength, and discovery of new possibilities. Post-traumatic growth coexists with ongoing fear and distress — it is a transformation that emerges alongside suffering, not in its absence.
Evidence-based interventions include CBT (first-line for depression and anxiety), mindfulness-based cognitive therapy (Carlson LE et al. — reduces cortisol, improves sleep and mood), and Meaning-Centered Psychotherapy (Breitbart WS — addresses existential concerns with RCT evidence). For women with ER-positive breast cancer on tamoxifen who need antidepressants: avoid paroxetine and fluoxetine (potent CYP2D6 inhibitors that significantly reduce endoxifen levels and may reduce tamoxifen efficacy); use sertraline, citalopram, or venlafaxine instead.
Health Behaviors That Shape Survivorship Outcomes
| Behavior | Evidence | Current Adherence |
|---|---|---|
| Exercise | 150 min/wk moderate aerobic + 2×/wk resistance (ACSM/ASCO 2022); reduces fatigue, depression, bone loss, cardiovascular risk; may reduce recurrence in breast/colon cancer | <20% of survivors meet guidelines in year 1 |
| Nutrition | Mediterranean pattern; adequate protein; weight management (obesity worsens outcomes in ER+ breast, endometrial, colon, kidney cancers) | Most survivors receive no formal nutrition counseling |
| Alcohol | IARC Group 1 carcinogen; increased breast cancer recurrence risk at ≥6 g/day (Kwan ML, JCO 2010); increases risk of second primary cancers | Many survivors continue use post-treatment |
| Smoking cessation | Reduces second primary risk; improves chemo/radiation efficacy; essential for tobacco-related cancer survivors | 15–20% of cancer survivors continue smoking after diagnosis |
| Maintenance therapy adherence | Completing prescribed adjuvant hormonal therapy, targeted therapy, or immunotherapy for full recommended duration — the most evidence-based survivorship intervention for many cancers | Adherence to 10-year AI therapy drops significantly at 5 years |
Exercise deserves special emphasis. Fewer than 20% of cancer survivors meet exercise guidelines in the first year after diagnosis, and most report that no healthcare provider specifically discussed exercise recommendations with them during survivorship care. Exercise is the single intervention in cancer survivorship supported by the broadest range of randomized trial evidence — improving outcomes across fatigue, mood, bone density, cardiovascular health, and potentially recurrence risk — and the most accessible. See the cancer recovery article for detailed exercise guidance.
Cancer Survivorship Disparities
Not all cancer survivors have equal access to survivorship care. Black women with breast cancer in the United States have a breast cancer mortality rate approximately 40% higher than white women, driven by higher proportions of triple-negative subtype, later stage at diagnosis, differences in treatment quality, higher comorbidity burden, and — at the survivorship stage — lower rates of survivorship care plan receipt and psychosocial support referral.
Survivors from lower socioeconomic backgrounds face compounding barriers: financial toxicity (independently associated with higher cancer mortality in Ramsey SD et al., J Clin Oncol 2016), reduced access to mental health services, and higher rates of unmet psychosocial needs. Rural cancer survivors face geographic barriers — fewer oncology specialists, longer travel distances, and greater reliance on primary care providers with limited cancer survivorship experience. For Hispanic and Latino survivors, language barriers and lower rates of navigated transition to survivorship care contribute to worse outcomes. Patient navigation programs are among the most effective interventions for reducing survivorship disparities.
Frequently Asked Questions
- Mullan F — Seasons of Survival; NEJM 1985
- IOM (National Academy of Medicine) — From Cancer Patient to Cancer Survivor: Lost in Transition; 2005
- American Cancer Society — Cancer Treatment & Survivorship Facts & Figures 2022–2024
- Friedman DL et al. (CCSS) — Subsequent neoplasms in 5-year childhood cancer survivors; J Clin Oncol 2010
- Armstrong GT et al. (CCSS) — Late mortality among 5-year survivors of childhood cancer; J Clin Oncol 2009
- Darby SC et al. — Cardiac effects of breast cancer radiation; NEJM 2013
- Simard S et al. — Fear of cancer recurrence meta-analysis; J Pain Symptom Manage 2013
- Butow PN et al. — Conquer Fear RCT; J Clin Oncol 2017
- Zaorsky NM et al. — Suicide among cancer patients; Nat Commun 2019
- Mitchell AJ et al. — Depression prevalence in oncology; Lancet Oncol 2011
- Campbell KL et al. (ACSM/ASCO 2022) — Exercise guidelines for cancer survivors
- Kwan ML et al. — Alcohol consumption and breast cancer recurrence; J Clin Oncol 2010
- Ramsey SD et al. — Financial insolvency and cancer mortality; J Clin Oncol 2016
- NCI Office of Cancer Survivorship: cancercontrol.cancer.gov/ocs
- NCI cancer survivorship: cancer.gov/about-cancer/coping/survivorship
This article is for educational purposes only and does not constitute medical advice. Discuss all cancer survivorship questions and healthcare decisions with your oncology care team.